MRI and PET to Assess Pembrolizumab Response — MPAK  

Malignant Melanoma, Metastatic Clinical Trial

Official title: A Feasibility Study of MRI and PET Imaging to Assess Response to MK-3475 (Pembrolizumab) in Patients With Metastatic Melanoma

Status Terminated

Clinical Trial Summary

The purpose of this study is to test two imaging techniques, one called whole body (WB) diffusion weighted (DWI) magnetic resonance imaging (MRI) (WB-DWI MRI), and another called Fluorine-18 3'-deoxy-3'-fluorothymidine positron emission tomography (PET) (F-18-FLT PET). The goal is to see whether these imaging techniques would allow the study doctors to see changes in the size of a tumor earlier for patients with metastatic melanoma receiving Pembrolizumab (MK-3475).

Clinical Trial Description

There is a growing body of evidence that demonstrates that tumor proliferation, measured classically by immunohistochemical evidence of increased Ki-67 expression, can be reliably determined in vivo using radiolabeled thymidine. The development of [18F]-fluorothymidine (FLT) PET has been reliably identified as a marker of cellular proliferation, and has been shown to identify changes in proliferation in successfully treated patients. ;

Related Conditions & MeSH terms

• Malignant Melanoma, Metastatic
• Melanoma

• NCT number: NCT02591654
• Study type: Interventional
• Source: Columbia University
• Status: Terminated
• Phase: Early Phase 1
• Start date: October 2015
• Completion date: October 2022